Prime Medicine, Inc. cash flow to debt ratio of -139.63% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Prime Medicine, Inc.'s free cash flow has decreased 28.38% from $-130.16M last year to $-167.09M, signaling decreasing performance

Prime Medicine, Inc.'s debt to equity ratio is 1.49, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Prime Medicine, Inc.'s debt has increased relative to shareholder equity from 0.27 last year to 1.49 today, signaling weakened financials

Prime Medicine, Inc. has negative EBITDA, making leverage ratio unreliable

Prime Medicine, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Prime Medicine, Inc.'s profit margin has increased (-25.11%) in the last year from -6.57K% to -4.92K%, signaling increasing performance

Prime Medicine, Inc.'s short-term assets of $181.29M exceed its short-term liabilities of $37.45M

Prime Medicine, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Prime Medicine, Inc.'s return on equity of -188.82%, is lower than 15.00%, indicating bad performance

Prime Medicine, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Prime Medicine, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Prime Medicine, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Prime Medicine, Inc. has negative free cash flow, indicating cash burn

Prime Medicine, Inc.'s yearly earnings has decreased 2.69% since last year from $-195.88M to $-201.14M, signaling decreasing performance

Prime Medicine, Inc.'s yearly revenue has increased 55.28% since last year from $2.98M to $4.63M, signaling increasing performance

ROIC -77.39% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Prime Medicine, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Prime Medicine, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Prime Medicine, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Prime Medicine, Inc. has insufficient data to evaluate this check.

Prime Medicine, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Prime Medicine, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Prime Medicine, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Prime Medicine, Inc. is overvalued relative to its fair value price of -11.80 based on Earnings Fair Value model

Prime Medicine, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Prime Medicine, Inc. has a price-to-book ratio of 8.01x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Prime Medicine, Inc. has a price-to-sales ratio of 152.19x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue